Most unbiased Wall Street analysts have a 12 month price target on Merck at something over $104 a share -- that's about a 20% upside, from today's NYSE price. This is so, because no matter what Tangerine 2.0 actually does (or, more precisely, is UNABLE to do, on pharma and health care delivery in the US). . . Rahway is exceedingly well-positioned, with a ~$28 billion a year juggernaut in immuno oncology -- into the mid 2030s.
As ever, do your own diligence, but here are the consenus Wall Street prognostications:
. . .The healthcare giant is gearing up to unveil its third-quarter results before the market opens on Thursday, Oct. 30. Ahead of the event, analysts expect MRK to deliver a profit of $2.37 per share, up 51% from $1.57 per share reported in the year-ago quarter. Further, the company has a solid earnings surprise history and has surpassed the Street’s bottom-line estimates in each of the past four quarters. . . .
For the full fiscal 2025, analysts expect MRK to deliver an EPS of $8.94, up 16.9% from $7.65 reported in 2024. While in fiscal 2026, its earnings are expected to grow 5.8% year-over-year to $9.46 per share. . . .
[Updated portion:] Strong demand for Winrevair from patients suffering from pulmonary arterial hypertension drove sales to $360 million in the third quarter of 2025, up 141.6% year-on-year.
Of MRK's vaccine franchise, its "gem" remains Capvaxive, which generated sales of $244 million for the quarter, a sharp 419.1% rise from the same period a year ago. . . . [end, updated portion.]
Analysts take an optimistic view of the stock’s prospects. MRK maintains a consensus “Moderate Buy” rating overall. Of the 25 analysts covering the stock, opinions include 11 “Strong Buys,” one “Moderate Buy,” and 13 “Holds.” Its mean price target of $102.43 suggests a 19.5% upside potential from current price levels. . . .
Smiling now, as I head into the gleaming steel and glass canyons for a sunny Fall day -- will find my favorite taco truck down there, too! Onward!
नमस्ते
No comments:
Post a Comment